title: Effect of an orally administered sulfonylurea, glipizide, for treatment of diabetes mellitus in cats.
abstract: An orally administered sulfonylurea drug, glipizide, was evaluated for treatment of diabetes mellitus. Confirmation of diabetes was based on evidence of appropriate clinical signs, persistent hyperglycemia, and glucosuria. Glipizide (5 mg, PO, q 12 h) was administered to each cat. Sixteen cats were fed a commercial high-fiber diet and 4 cats were fed a commercial low-fiber diet. Insulin was not administered to any cat during the study. Each cat was evaluated 2, 4, 8, and 12 weeks after initiation of treatment. Three clinical responses to glipizide treatment were identified. Mean preprandial blood glucose concentration and mean blood glucose concentration during an 8-hour postprandial period decreased to < 200 mg/dl in 5 of 20 (25%) cats. In these 5 cats, glucosuria was no longer detected and clinical signs resolved by the 4-week reevaluation. Euglycemia was maintained after discontinuing glipizide treatment in 2 of these 5 cats. Glycemic control has been maintained in 2 of 5 of the responding cats for 5 and 7 months of glipizide treatment. One of 5 of the responding cats developed insulin-requiring diabetes mellitus after 6 months of glipizide treatment. Seven of 20 (35%) cats failed to respond to treatment. Mean preprandial blood glucose concentration and mean blood glucose concentration during an 8-hour postprandial period did not change from pretreatment values after 2 +/- 1 months; glucosuria persisted and clinical signs progressively worsened. Insulin treatment was required to establish glycemic control in these 7 cats. Eight of 20 (40%) cats partially responded to glipizide treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, School of Veterinary Medicine, University of California, CA 95616.
authors.forename: R W
authors.initials: RW
authors.lastname: Nelson
authors.forename: E C
authors.initials: EC
authors.lastname: Feldman
authors.forename: S L
authors.initials: SL
authors.lastname: Ford
authors.forename: O P
authors.initials: OP
authors.lastname: Roemer
mesh_terms: D000284:Administration, Oral; D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D001835:Body Weight; D002371:Cat Diseases / Q000188:drug therapy*; D002415:Cats; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000662:veterinary*; D004043:Dietary Fiber; D005260:Female; D005500:Follow-Up Studies; D005913:Glipizide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005951:Glucose Tolerance Test / Q000662:veterinary; D007328:Insulin / Q000097:blood / Q000627:therapeutic use; D008297:Male; D012189:Retrospective Studies; D014839:Vomiting / Q000139:chemically induced / Q000662:veterinary
chemical_list: D001786:Blood Glucose; D004043:Dietary Fiber; D007328:Insulin; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D005913:Glipizide